Trilogy Capital Inc. Decreases Holdings in Amgen Inc. $AMGN

by · The Markets Daily

Trilogy Capital Inc. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 91.8% during the second quarter, HoldingsChannel reports. The firm owned 833 shares of the medical research company’s stock after selling 9,302 shares during the quarter. Trilogy Capital Inc.’s holdings in Amgen were worth $302,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares during the period. Schnieders Capital Management LLC. raised its stake in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after buying an additional 5,853 shares during the period. Main Street Financial Solutions LLC lifted its position in shares of Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after buying an additional 416 shares during the last quarter. Finally, Ieq Capital LLC grew its stake in shares of Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. BMO Capital Markets boosted their price objective on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday. Truist Financial boosted their price target on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research report on Wednesday. Robert W. Baird raised their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday. TD Cowen lifted their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, UBS Group boosted their target price on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $367.57.

View Our Latest Research Report on AMGN

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

  • Positive Sentiment: Q2 results surpassed expectations. Amgen reported adjusted EPS of $6.29 versus consensus of approximately $5.62 and revenue of $10.05 billion versus estimates near $9.43 billion. Revenue rose 9.5% year over year. Amgen Q2 earnings and revenue results
  • Positive Sentiment: Management raised its full-year outlook. Amgen now expects 2026 revenue of $38.2 billion to $39.4 billion, above the prior consensus of roughly $37.8 billion, while adjusted EPS guidance is $22.30 to $23.50. Strong demand for Repatha, Evenity and rare-disease medicines helped offset declines in legacy products. Amgen drug growth and outlook
  • Positive Sentiment: Several analysts increased their price targets. UBS raised its target to $440, TD Cowen to $452, Scotiabank to $450 and BMO Capital Markets to $450, with buy or outperform ratings. Analysts also cited Amgen’s late-stage pipeline and continued product momentum. Amgen analyst price-target changes
  • Neutral Sentiment: Analyst opinion remains divided. While several firms became more bullish, Wells Fargo, Morgan Stanley, Canaccord and Truist retained equal-weight or hold ratings, and Bank of America and Baird maintained underperform ratings.
  • Negative Sentiment: Pipeline and regulatory risks remain. Amgen halted development of an early-stage obesity treatment, while older drugs such as Prolia and XGEVA face biosimilar pressure. Reports also cited a patient-data breach investigation and scrutiny of clinical data supporting Tavneos, creating potential legal, reputational and operational risks. Amgen data breach and Tavneos risks

Amgen Trading Up 4.6%

Shares of AMGN opened at $407.83 on Thursday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $416.24. The stock has a market cap of $220.11 billion, a PE ratio of 25.35, a P/E/G ratio of 3.95 and a beta of 0.41. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The business’s 50-day moving average price is $359.92 and its 200-day moving average price is $355.33.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 132.73%. Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s dividend payout ratio is currently 70.15%.

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).